Ayala Pharmaceuticals Zukünftige P/E

Was ist das Zukünftige P/E von Ayala Pharmaceuticals?

Zukünftige P/E von Ayala Pharmaceuticals Inc. ist -0.14

Was ist die Definition von Zukünftige P/E?



Das Terminkurs-Gewinn-Verhältnis ist das Verhältnis des Aktienkurses eines Unternehmens zum geschätzten Gewinn des Unternehmens für die nächsten zwölf Monate.

The forward price to earnings ratio is similar to trailing price to earnings ratio but instead of net income uses estimated net earnings over next 12 months. Estimates are typically derived as the mean of those published by a select group of analysts with selection criteria varying. The forward price-to-earnings ratio is a powerful, but limited tool. It allows a quick snapshot of the company’s finances without getting down in the details of an accounting report.

Zukünftige P/E von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Ayala Pharmaceuticals

Was macht Ayala Pharmaceuticals?

advaxis (nasdaq: adxs) is a late -stage biotechnology company developing multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer. the advaxis technology, using bioengineered live attenuated bacteria, listeria monocytogenes (lm), actively suppresses key components in the tumor microenvironment that contribute to the tumors growth and protection from immunologic attack.

Unternehmen mit zukünftige p/e ähnlich Ayala Pharmaceuticals